Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system
is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive
bladder cancer (NMIBC) between diagnosis and transurethral resection of bladder tumors
(TURBT)